Cargando…

Bcl‐2 inhibitors enhance FGFR inhibitor‐induced mitochondrial‐dependent cell death in FGFR2‐mutant endometrial cancer

Endometrial cancer is the most commonly diagnosed gynaecological malignancy. Unfortunately, 15–20% of women demonstrate persistent or recurrent tumours that are refractory to current chemotherapies. We previously identified activating mutations in fibroblast growth factor receptor 2 (FGFR2) in 12% (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Packer, Leisl M., Stehbens, Samantha J., Bonazzi, Vanessa F., Gunter, Jennifer H., Ju, Robert J., Ward, Micheal, Gartside, Michael G., Byron, Sara A., Pollock, Pamela M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441928/ https://www.ncbi.nlm.nih.gov/pubmed/30537101 http://dx.doi.org/10.1002/1878-0261.12422

Ejemplares similares

FGFR2 Point Mutations in 466 Endometrioid Endometrial Tumors: Relationship with MSI, KRAS, PIK3CA, CTNNB1 Mutations and Clinicopathological Features
por: Byron, Sara A., et al.
Publicado: (2012)

Correction: FGFR2 Point Mutations in 466 Endometrioid Endometrial Tumors: Relationship with MSI, KRAS, PIK3CA, CTNNB1 Mutations and Clinicopathological Features
por: Byron, Sara A., et al.
Publicado: (2012)

Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
por: Facchinetti, Francesco, et al.
Publicado: (2023)

FGFR redundancy limits the efficacy of FGFR4-selective inhibitors in hepatocellular carcinoma
por: Tao, Zhanchao, et al.
Publicado: (2022)

Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors
por: Javle, Milind, et al.
Publicado: (2023)

Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer
por: Weickhardt, Andrew J., et al.
Publicado: (2022)

RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
por: Subbiah, Vivek, et al.
Publicado: (2023)

FGFR-2 and Epithelial–Mesenchymal Transition in Endometrial Cancer
por: Adamczyk-Gruszka, Olga, et al.
Publicado: (2022)

Intrahepatic Cholangiocarcinoma: State of the Art of FGFR Inhibitors
por: Wu, Tianyu, et al.
Publicado: (2021)

Spatial expression of the FGFR2b splice isoform and its prognostic significance in endometrioid endometrial carcinoma
por: Sengal, Asmerom T, et al.
Publicado: (2022)

Growth charts in FGFR2- and FGFR3-related faciocraniosynostoses
por: Ea, Caroline, et al.
Publicado: (2022)

Enhanced FGFR signalling predisposes pancreatic cancer to the effect of a potent FGFR inhibitor in preclinical models
por: Zhang, H, et al.
Publicado: (2014)

Targeting the Src Pathway Enhances the Efficacy of Selective FGFR Inhibitors in Urothelial Cancers with FGFR3 Alterations
por: Lima, Nadia Carvalho, et al.
Publicado: (2020)

Mechanisms of resistance to FGFR1 inhibitors in FGFR1-driven leukemias and lymphomas: implications for optimized treatment
por: Cowell, John K., et al.
Publicado: (2021)

Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment
por: Ruan, Ruiwen, et al.
Publicado: (2023)

Novel mutation detection of fibroblast growth factor receptor 1 (FGFR1) gene, FGFR2IIIa, FGFR2IIIb, FGFR2IIIc, FGFR3, FGFR4 gene for craniosynostosis: A prospective study in Asian Indian patient
por: Barik, Mayadhar, et al.
Publicado: (2015)

BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression
por: Kim, Se Hyun, et al.
Publicado: (2018)

ASP5878, a selective FGFR inhibitor, to treat FGFR3‐dependent urothelial cancer with or without chemoresistance
por: Kikuchi, Aya, et al.
Publicado: (2017)

Expression Atlas of FGF and FGFR Genes in Pancancer Uncovered Predictive Biomarkers for Clinical Trials of Selective FGFR Inhibitors
por: Li, Yuan, et al.
Publicado: (2020)

FGFR inhibitors in cholangiocarcinoma: what’s now and what’s next?
por: Saborowski, Anna, et al.
Publicado: (2020)

Radiosensitization by the Selective Pan-FGFR Inhibitor LY2874455
por: Darwis, Narisa Dewi Maulany, et al.
Publicado: (2022)

Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma
por: Benjamin, David J, et al.
Publicado: (2022)

Futibatinib: second EMA approval for FGFR inhibitor in cholangiocarcinoma
por: Lamarca, A., et al.
Publicado: (2023)

FGFR2 amplification in colorectal adenocarcinoma
por: Carter, Jamal H., et al.
Publicado: (2017)

Rapidly Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in NSCLC Cell Lines through De-Repression of FGFR2 and FGFR3 Expression
por: Ware, Kathryn E., et al.
Publicado: (2010)

Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer
por: Jogo, Tomoko, et al.
Publicado: (2021)

Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models
por: Grünewald, Sylvia, et al.
Publicado: (2019)

Intrinsic FGFR2 and Ectopic FGFR1 Signaling in the Prostate and Prostate Cancer
por: Wang, Cong, et al.
Publicado: (2019)

The Evaluation of FGFR1, FGFR2 and FOXO1 in Orofacial Cleft Tissue
por: Goida, Jana, et al.
Publicado: (2022)

BCL2 enhances survival of porcine pluripotent stem cells through promoting FGFR2
por: Zhu, Zhenshuo, et al.
Publicado: (2020)

The Roles of TP53 and FGFR2 in Progress Made Treating Endometrial Cancer
por: Adamczyk-Gruszka, Olga, et al.
Publicado: (2022)

Fibroblast Growth Factor Receptor (FGFR) Inhibitors in Urothelial Cancer
por: Garje, Rohan, et al.
Publicado: (2020)

FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice
por: Kommalapati, Anuhya, et al.
Publicado: (2021)

Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors
por: Rizzo, Alessandro
Publicado: (2021)

Structural insights into the potency and selectivity of covalent pan-FGFR inhibitors
por: Qu, Lingzhi, et al.
Publicado: (2022)

Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric Rhabdomyosarcoma
por: Wu, Jerry T., et al.
Publicado: (2023)

Clinical development and management of adverse events associated with FGFR inhibitors
por: Subbiah, Vivek, et al.
Publicado: (2023)

Expression and clinical significance of FGFR1 and FGFR2 in laryngeal squamous cell carcinoma
por: Hu, Mengdie, et al.
Publicado: (2022)

An Alignment-Independent 3D-QSAR Study of FGFR2 Tyrosine Kinase Inhibitors
por: Jafari, Behzad, et al.
Publicado: (2017)

Preclinical Evaluation of the Pan-FGFR Inhibitor LY2874455 in FRS2-Amplified Liposarcoma
por: Hanes, Robert, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ep81lfhahs8sr81p1ajmnj4o12